Answers are grounded in this paper and cite their sources.
Multidrug-resistant Gram-positive pathogens such as vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and methicillin-resistant coagulase-negative staphylococci account for a significant number of nosocomial infections, and new options for therapy have been lacking. During the past year, two agents have been released that have activity against these organisms: quinupristin/dalfopristin and linezolid. Although neither agent is a panacea, these recently released agents offer new options for therapy.
No takes yet. Share an insight, caveat, or question.
Jan E. Patterson (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: